TABLE 1.

Hair cell survival (percent of control) and ED₅₀ of protection after pretreatment with increasing doses of quinoline derivative followed by 200 μM neomycin treatment

Drug	Protective drug concentration						ED50 (μM)	Treatment effect; p value (ANOVA)
	0 μM	10 μM	50 μM	100 μM	200 μM	Drug alone (no neo)
Amsacrine	16 ± 6	103 ± 12**	108 ± 10**	102 ± 19**	102 ± 8**	107 ± 10	4	F(4, 43) = 105.51, p < 0.0001
Quinine	24 ± 9	94 ± 10**	101 ± 12**	102 ± 10**	74 ± 28**	64 ± 24	4	F(4, 45) = 41.34, p < 0.0001
Mefloquine	20 ± 6	88 ± 8**	95 ± 13**	103 ± 17**	85 ± 14**	82 ± 11	6	F(4, 40) = 73.48, p < 0.0001
Cinchonidine	18 ± 8	59 ± 15**	91 ± 15**	99 ± 7**	103 ± 11**	101 ± 8	160	F(4, 45) = 91.46, p < 0.0001
Amodiaquine	13 ± 8	49 ± 7**	64 ± 18**	85 ± 15**	101 ± 8**	94 ± 9	40	F(4, 44) = 51.19, p < 0.0001
Chloroquine	33 ± 13	30 ± 20	64 ± 16**	65 ± 20**	95 ± 10**	104 ± 11	50	F(4, 41) = 25.15, p < 0.0001
Cinchonine	17 ± 11	52 ± 13**	50 ± 9**	61 ± 10**	78 ± 12**	104 ± 18	64	F(4, 43) = 37.15, p < 0.0001
Tacrine	15 ± 6	22 ± 7	41 ± 8**	53 ± 10**	86 ± 16**	106 ± 12	92	F(4, 45) = 74.83, p < 0.0001

Drug alone column indicates hair cell survival in the presence of 200 μM quinoline derivative without neomycin

**p < 0.01, Tukey HSD test